Procarta Biosystems strengthens management team
This article was originally published in Scrip
Procarta Biosystems, a private UK company focused on approaches to counter antibiotic resistance, has appointed John Hodgsonto its board of directors. He has more than 25 years' management experience in the pharmaceutical and biotechnology sectors, having worked at Beecham Pharmaceuticals (which became SmithKline Beecham Pharmaceuticals while he was at the company), Novexel and Hoescht Marion Roussel,
You may also be interested in...
Ability to quickly scale manufacturing is a key criteria for Operation Warp Speed therapeutics, but for monoclonal antibodies the most effective approach may mean fewer doses. FDA’s Janet Woodcock said the government is supporting a range of antibody approaches for COVID-19 so that if virus escape mutants emerge from single antibody treatment there will be other options, while Regeneron argues the cocktail approach is safer, even though it will likely mean fewer doses of drug will be available.
German sickness insurance funds are under unusual financial pressure as a result of the COVID-19 pandemic. And a recent decision to reduce reimbursement for COVID-19 confirmatory tests by one third has left testing labs and diagnostics makers frustrated. See what Martin Walger, chief executive of the German diagnostic industry association (VDGH) said about it here.
US FDA adds brucellosis, opisthorchiasis and paragonimiasis to the list of qualifying diseases but declines to include clonorchiasis and coccidioidomycosis, finding a significant market in developed nations for treatments or vaccines addressing the two conditions.